[go: up one dir, main page]

LT2004074A - Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti - Google Patents

Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti

Info

Publication number
LT2004074A
LT2004074A LT2004074A LT2004074A LT2004074A LT 2004074 A LT2004074 A LT 2004074A LT 2004074 A LT2004074 A LT 2004074A LT 2004074 A LT2004074 A LT 2004074A LT 2004074 A LT2004074 A LT 2004074A
Authority
LT
Lithuania
Prior art keywords
neoplazinems
metalproteinazes
matricines
ligoms
kompozicija
Prior art date
Application number
LT2004074A
Other languages
English (en)
Other versions
LT5215B (lt
Inventor
Matthias Rath
Shrirang Netke
Vadim Ivanov
Waheed Roomi
Aleksandra Niedzwiecki
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of LT2004074A publication Critical patent/LT2004074A/lt
Publication of LT5215B publication Critical patent/LT5215B/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
LT2004074A 2002-01-08 2004-08-05 Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti LT5215B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/041,427 US6939860B2 (en) 2002-01-08 2002-01-08 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds

Publications (2)

Publication Number Publication Date
LT2004074A true LT2004074A (lt) 2004-12-27
LT5215B LT5215B (lt) 2005-05-25

Family

ID=21916454

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2004074A LT5215B (lt) 2002-01-08 2004-08-05 Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti

Country Status (29)

Country Link
US (3) US6939860B2 (lt)
EP (1) EP1463498B1 (lt)
JP (1) JP4144800B2 (lt)
KR (1) KR20050005408A (lt)
CN (1) CN1612731A (lt)
AT (1) ATE439833T1 (lt)
AU (2) AU2002244690A1 (lt)
BR (1) BR0208052A (lt)
CA (1) CA2469162A1 (lt)
CZ (1) CZ2004853A3 (lt)
DE (1) DE60233433D1 (lt)
EE (1) EE200400031A (lt)
ES (1) ES2332126T3 (lt)
HR (1) HRP20040705A2 (lt)
HU (1) HUP0402421A3 (lt)
IL (1) IL162384A0 (lt)
LT (1) LT5215B (lt)
LV (1) LV13249B (lt)
MX (1) MXPA04006627A (lt)
NO (1) NO20033949L (lt)
NZ (1) NZ533353A (lt)
PL (1) PL371205A1 (lt)
RU (1) RU2284185C2 (lt)
SI (1) SI21871A (lt)
SK (1) SK2772004A3 (lt)
TR (1) TR200401669T1 (lt)
UA (1) UA78979C2 (lt)
WO (1) WO2003057211A1 (lt)
ZA (1) ZA200404915B (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669282B2 (en) * 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US6939860B2 (en) * 2002-01-08 2005-09-06 Matthias Rath Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
US20050079234A1 (en) * 2003-08-27 2005-04-14 Chiang Yang Chi Compositions comprising herbs and method for immunomodulation
KR20050070385A (ko) * 2003-12-30 2005-07-07 (주)현덕비엔티 폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는항암치료 보조용 조성물
WO2006053184A2 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing a vascular disease
ES2246737B1 (es) * 2005-06-09 2006-12-01 Jose Juan Rodriguez Jerez "composicion farmaceutica que comprende lisina y usos correspondientes".
ES2497766T3 (es) * 2005-12-29 2014-09-23 Mitsui Norin Co., Ltd Composiciones y procedimientos de sensibilizar a oxacilina Staphylococcus aureus resistente a meticilina
US20070265211A1 (en) * 2006-05-12 2007-11-15 Matthias Rath Novel composition and method effective in inhibiting the atherogenic process
WO2010025335A2 (en) * 2008-08-29 2010-03-04 Dr Pepper/Seven Up, Inc. Functional consumable compositions for promoting skin health and methods for using the same
EP2179722A1 (en) * 2008-10-24 2010-04-28 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Topical formation for preventing sexual transmission of viral infection
ES2534245T3 (es) 2008-11-04 2015-04-20 Vymedic, Llc Formulaciones de suplemento antiviral
CN102656133B (zh) * 2009-10-16 2015-04-15 株式会社钟化 还原型辅酶q10的制造方法、稳定化方法以及含有还原型辅酶q10的组合物
EP2648721B1 (de) 2011-01-31 2018-09-19 LUCOLAS-M.D. Ltd. Kombinationen von aromatase inhibitoren und antioxidanzien
KR101829330B1 (ko) 2011-04-13 2018-02-20 (주)아모레퍼시픽 염증성 피부 노화 억제 물질 스크리닝 방법
CN102526170B (zh) * 2011-12-31 2015-04-29 许学志 抗结核杆菌的儿茶提取物组合物、其制备方法及含有它们的药物制剂和应用
BE1023772B9 (fr) * 2013-05-17 2017-08-02 Valore Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
CN104096058A (zh) * 2014-07-02 2014-10-15 胥玲 一种治疗扩张型心肌病的中药药丸
BE1022579A9 (fr) * 2014-11-10 2016-10-06 Valore Composition antimétastatique comprenant au moins un composé de type flavanol
IT202200013867A1 (it) * 2022-06-30 2023-12-30 Lo Li Pharma Srl Composizione per il trattamento dell’ infezione da papilloma virus (hpv)
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
RU2170232C2 (ru) * 1996-08-28 2001-07-10 Дзе Проктер Энд Гэмбл Компани Амиды фосфиновых кислот и способ предупреждения или лечения заболевания, связанного с нежелательной активностью металлопротеазы
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6646013B1 (en) 1999-06-15 2003-11-11 Nutri-Logics Nutrient formulations for disease reduction
US6939860B2 (en) * 2002-01-08 2005-09-06 Matthias Rath Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
ES2299689T3 (es) * 2002-02-25 2008-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas.

Also Published As

Publication number Publication date
PL371205A1 (en) 2005-06-13
AU2002244690A1 (en) 2003-07-24
JP4144800B2 (ja) 2008-09-03
TR200401669T1 (tr) 2007-01-22
CN1612731A (zh) 2005-05-04
ES2332126T3 (es) 2010-01-27
DE60233433D1 (de) 2009-10-01
SK2772004A3 (en) 2004-12-01
LV13249B (en) 2005-07-20
HUP0402421A2 (hu) 2005-07-28
UA78979C2 (en) 2007-05-10
US6939860B2 (en) 2005-09-06
IL162384A0 (en) 2005-11-20
HRP20040705A2 (en) 2004-10-31
JP2005513166A (ja) 2005-05-12
RU2004124047A (ru) 2005-04-20
CA2469162A1 (en) 2003-07-17
US20050032715A1 (en) 2005-02-10
ATE439833T1 (de) 2009-09-15
CZ2004853A3 (cs) 2004-12-15
EP1463498B1 (en) 2009-08-19
BR0208052A (pt) 2005-01-04
EE200400031A (et) 2004-04-15
LT5215B (lt) 2005-05-25
HUP0402421A3 (en) 2008-02-28
EP1463498A1 (en) 2004-10-06
US20050281794A1 (en) 2005-12-22
NZ533353A (en) 2007-04-27
NO20033949L (no) 2003-11-04
WO2003057211A1 (en) 2003-07-17
AU2008203157A1 (en) 2008-08-07
RU2284185C2 (ru) 2006-09-27
ZA200404915B (en) 2006-07-26
US20030130201A1 (en) 2003-07-10
MXPA04006627A (es) 2004-11-10
SI21871A (sl) 2006-04-30
NO20033949D0 (no) 2003-09-05
KR20050005408A (ko) 2005-01-13

Similar Documents

Publication Publication Date Title
LT2004074A (lt) Matricines metalproteinazes inhibuojanti kompozicija neoplazinėms ligoms gydyti
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
GB0223038D0 (en) Therapeutic compounds
DE60332163D1 (de) Zusammensetzung zur hautaufhellung
TR200901979T2 (tr) Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri.
YU101503A (en) A novel engineered superantigen for human therapy
MX2007006397A (es) Derivados de tetrahidropirano.
NZ331327A (en) Serine protease inhibitors having an acylguanidine side chain
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
FR2818906B1 (fr) Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
DE60018186D1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
DE50114181D1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
SE0301883D0 (sv) New use II
EP1251847A4 (en) NEW USE OF PRODIGIOSINE TO TREAT DIABETES
ATE242763T1 (de) Methoximinophenylessigsäureamide
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
MXPA05012605A (es) Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
AU6722498A (en) Disubstituted biphenyloxazolines
MXPA04000876A (es) Derivados de acido butirico.
HU0201195D0 (lt)
FR2842109B1 (fr) Utilisation d'un extrait de chrysanthellum
IL164536A0 (en) The use of hydroxypyridone-derivatives in wound healing